TL938 with Trastuzumab for HER2+ Colorectal Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a new combination of drugs (TL938 and trastuzumab) for people with a specific type of advanced colorectal cancer that is HER2-positive and RAS wild-type. It may offer a new option if you have already tried standard chemotherapy and a blood vessel-blocking drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your colorectal cancer must be HER2-positive and RAS wild-type, and it has spread to other parts of the body or cannot be removed with surgery.
- You should have already tried chemotherapy (like fluorouracil, oxaliplatin, and irinotecan) and a drug that blocks blood vessel growth (such as Avastin).
- You must have at least one tumor that can be measured on imaging scans.
- You cannot have had any prior treatment that targets the HER2 protein directly.
- You cannot have active brain metastases that are causing symptoms or need steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
This trial tests a combination of two targeted therapies, Trastuzumab Deruxtecan (T-DXd) and Cetuximab, for people with colorectal cancer that has spread or cannot be removed by surgery. It is for those whose tumors have low levels of a protein called HER2 and who have already tried certain standard treatments.
This trial tests a combination of three drugs (trastuzumab deruxtecan, capecitabine, and bevacizumab) as the first treatment for people with HER2-positive colorectal cancer that has spread or cannot be removed by surgery. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two targeted drugs — anlotinib (which cuts off a tumor's blood supply) and trastuzumab deruxtecan (which attacks HER2-low cancer cells) — for advanced breast cancer that has stopped responding to previous treatments.
This trial tests a combination of two targeted drugs (against HER2 and EGFR) plus chemotherapy for people with a specific type of advanced colorectal cancer that has spread and stopped responding to standard treatments. It aims to see if this new approach can shrink tumors or slow the cancer's growth.
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
Hear when a new Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.